Original article| Volume 21, ISSUE 2, e39-e48, June 2022

Download started.


Evaluation of Clinical and Pathological Factors to Predict High Risk of Recurrence in Patients With Stage II Colon Cancer

Published:October 02, 2021DOI:


      Background: The ability to predict patients with stage II colon cancer at high risk of recurrence is currently limited to certain clinicopathologic factors. Patients and Methods: This population-based study reviewed various prognostic factors to identify those associated with worse time to recurrence (TTR) and improved disease-specific survival (DSS), and to subsequently develop a prognostic index (PI) to identify high risk cancers. Results: Multivariate analyses revealed factors significant for TTR and DSS. A PI derived from the TTR risk factors identified 3 risk groups using 5-year rate without relapse: 88% for low-risk, 81% for intermediate-risk, and 59% for high risk. Conclusion: This model was better at identifying high risk patients than using equally weighted standard risk factors.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • O'Connell M.J.
        • Campbell M.E.
        • Goldberg R.M.
        • et al.
        Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
        J Clin Oncol. 2008; 26: 2336-2341
        • Sargent D.
        • Sobrero A.
        • Grothey A.
        • et al.
        Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
        J Clin Oncol. 2009; 27: 872-877
        • Benson 3rd, A.B.
        • Schrag D.
        • Somerfield M.R.
        • et al.
        American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
        J Clin Oncol. 2004; 22: 3408-3419
        • Venook A.P.
        • Niedzwiecki D.
        • Lopatin M.
        • et al.
        Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
        J Clin Oncol. 2013; 31: 1775-1781; 10.1200/JCO.2012.45.1096
        • Gill S.
        • Loprinzi C.L.
        • Sargent D.J.
        • et al.
        Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?.
        J Clin Oncol. 2004; 22: 1797-1806
        • O'Connor E.S.
        • Greenblatt D.Y.
        • LoConte N.K.
        • et al.
        Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.
        J Clin Oncol. 2011; 29: 3381-3388; 10.1200/JCO.2010.34.3426
        • Tournigand C.
        • Andre T.
        • Bonnetain F.
        • et al.
        Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial.
        J Clin Oncol. 2012; 30: 3353-3360; 10.1200/JCO.2012.42.5645
        • Kumar A.
        • Kennecke H.F.
        • Renouf D.J.
        • et al.
        Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
        Cancer. 2015; 121: 527-534
        • Casadaban L.
        • Rauscher G.
        • Aklilu M.
        • Villenes D.
        • Freels S.
        • Maker A.V.
        Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.
        Cancer. 2016; 122: 3277-3287
        • Yothers G.
        • O'Connell M.J.
        • Lee M.
        • et al.
        Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
        J Clin Oncol. 2013; 31: 4512-4519
        • Niedzwiecki D.
        • Frankel W.L.
        • Venook A.P.
        • et al.
        Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (alliance).
        J Clin Oncol. 2016; 34: 3047-3053
        • Harrell F.E.
        • Lee K.L.
        • Mark D.B.
        Tutorial in biostatistics: multivariable prognostic models.
        Stat Med. 1996; 15: 361-387
        • Miao Y.
        • Stijacic Cenzer I.
        • Boscardin J
        Estimating Harrell's Optimism on Predictive Indices Using Bootstrap Samples.
        SAS Global Forum, 2013
        • Machin D.
        • Cheung Y.B.
        • Parmar M.K.
        Chapter 8 prognostic indices.
        Survival Analysis: A practical Approach. 2nd ed. John Wiley and Sons, West Sussex, England2006
        • Edge S.B.
        • Compton C.C.
        The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
        Ann Surg Oncol. 2010; 17: 1471-1474
        • Kennecke H.
        • Yin Y.
        • Davies J.
        • Speers C.
        • Cheung W.
        • Lee-Ying R.
        Prognostic effect of sidedness in early stage versus advanced colon cancer.
        Health Sci Rep. 2018; 1: e54
        • Li Y.
        • Feng Y.
        • Dai W.
        • Li Q.
        • Cai S.
        • Peng J.
        Prognostic effect of tumor sidedness in colorectal cancer: a SEER-based analysis.
        Clin Colorectal Cancer. 2019; 18 (S1533-0028(18)30456-0): e104-e116
        • Tie J.
        • Wang Y.
        • Tomasetti C.
        • et al.
        Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
        Sci Transl Med. 2016; 6 (8346ra92)
        • Faulds J.
        • McGahan C.E.
        • Phang P.T.
        • Raval M.J.
        • Brown C.J.
        Differences between referred and nonreferred patients in cancer research.
        Can J Surg. 2013; 56: E135-E141